Fusion Antibodies

9 results

Belfast research contract group Fusion Antibodies reported record second-half revenues as it moves past AIM-listing pressures.
Fusion Antibodies sees full year revenues dip 19%

Northern Ireland contract research company Fusion Antibodies recorded a 19 per cent fall in full year revenues to £2.2 million on the back of a weak f(...)

Photograph: iStock
Fusion Antibodies confirms second-half pick-up in revenue

Belfast-based Fusion Antibodies said its performance in the second half of the year ended March 31st improved as orders and revenues significantly inc(...)

Paul Kerr, chief executive of Fusion Antibodies.
Fusion Antibodies warns of weaker revenues for 2019

Northern Ireland contract research company Fusion Antibodies warned that revenues for the year ended March 31st would be “materially below current mar(...)

Fusion Antibodies CEO Paul Kerr said it had been a challenging period but company had ‘turned a corner’.
Losses at Fusion Antibodies quadruple in ‘challenging’ period

Losses at Belfast pharmaceutical company Fusion Antibodies quadrupled in the six months ended September 30th compared with the same period last year, (...)

Fusion Antibodies has a particular focus on the production of antibodies in a lab. Photograph: iStock
Fusion Antibodies reports £700,000 loss for first trading year

Fusion Antibodies, the Northern Ireland contract research company, has reported losses of nearly £700,000 (€781,000) for its maiden year as an AIM-lis(...)

Shares dive in NI-based clinical trials group

Fusion Antibodies, the Belfast-based contract research organisation, has issued a profit warning after it disclosed that trading for the current finan(...)

Fusion Antibodies said the outlook for the next trading year is a positive one. Photograph: iStock
Fusion Antibodies flags full year revenues behind expectations

Belfast pharmaceutical company Fusion Antibodies said it expects revenues for the trading year ended March 31st 2018 to grow at least 40 per cent on t(...)

Fusion Antibodies placed 6,707,317 ordinary shares on AIM at a price of £0.82
Fusion Antibodies raises £5.5m in London Stock Exchange debut

Belfast pharma company Fusion Antibodies has raised £5.5 million (€6.2m) in its debut on the junior market of the London Stock Exchange. Fusion, a c(...)

Embo Medical (from left) Wayne Allen, Colin Forde and Liam Mullins. The firm was voted “one-to watch” by the CorkBIC Venture Academy.
Innovation finalists: making a difference in medical industry

Embo Medical Embo Medical has created a new medical device which makes embolization procedures faster and less expensive while also offering mo(...)